On April 2, 2026 — the one-year anniversary of his original “Liberation Day” tariffs that the Supreme Court struck down — President Trump signed a new executive order imposing 100% tariffs on branded pharmaceutical imports. The legal basis this time is Section 232 of the Trade Expansion Act, not the emergency powers law the Court already rejected. Same instinct, different statute.
100% — default rate on patented drug imports and active ingredients
20% — for companies with approved plans to manufacture in the U.S. (rises to 100% by April 2030 if they don’t follow through)
15% — for imports from the EU, Japan, South Korea, Switzerland
10% — for United Kingdom (may drop to zero under a future bilateral deal)
0% — for companies that commit to both onshore manufacturing AND “most favored nation” pricing (pegged to prices in other wealthy countries)
The exemption for companies entering MFN deals is slated to sunset on January 20, 2029 — the day Trump leaves office. Meaning any deal struck today could be torn up by the next president, or by Trump himself if he changes his mind. That’s not trade policy. That’s a loyalty test with an expiration date.
Who Gets a Pass
Major drugmakers including Pfizer, Merck, Bristol Myers Squibb, and AstraZeneca have already struck confidential deals with the White House and face zero tariffs. Under those agreements, they broadly agreed to offer many of their medicines to Medicaid at MFN prices and committed to building new facilities in the U.S. Generic drugs, biosimilars, orphan drugs, nuclear medicines, plasma-derived therapies, and fertility treatments are all exempt. The administration says generic tariffs will be “reassessed in one year.”
A senior administration official told reporters they anticipate “the lion’s share” of patented drugs consumed by Americans will be made in the United States. “We need to make sure our drug supply is protected, secure, and domestic,” the official said. The Commerce Department investigation that preceded the order concluded that U.S. reliance on foreign pharmaceutical manufacturing — with roughly 53% of domestically distributed drugs produced overseas — poses a threat to national security and public health.
The Price Tag
According to the Budget Lab at Yale, all tariffs in effect as of April 8, 2026 (including the pharma tariffs) bring the U.S. average effective tariff rate to 11.8% — the highest since the early 1940s (excluding the 2025 tariff rates that were struck down). The ultimate price-level impact is estimated between 0.5% and 0.7%, representing a loss of $760 to $940 for the average American household.
“96% of the costs are borne on the U.S. side. Companies that are paying when they bring it in — their suppliers are not lowering prices.” — Dan Anthony, Executive Director, We Pay the Tariffs
U.S. manufacturing output is projected to expand by 1.1% in the long run under current tariff policy. But those gains are “more than crowded out” by contractions elsewhere: construction output is projected to fall 2.5%, mining by 1.0%. The net effect on GDP is negative — the economy is persistently 0.1% smaller, equivalent to about $30 billion annually in lost output.
The Pattern
This is the third attempt at tariff policy in 15 months. The IEEPA “Liberation Day” tariffs were struck down by the Supreme Court. The replacement 10% global tariff under Section 122 is set to expire in 150 days. Now Section 232 for pharmaceuticals. Each time the legal basis changes, but the approach is the same: threaten massive tariffs, then offer exemptions to companies willing to play ball with the White House. The companies that cooperate get favorable treatment. The ones that don’t get punished. The costs flow to consumers and small businesses.
For patients, the math is straightforward. If your drug is made by a company that struck a deal with the administration, nothing changes. If it isn’t — or if you take a drug that’s manufactured overseas by a company that didn’t agree to the White House’s terms — the import cost just doubled. And in a country where 53% of drugs come from abroad, that’s a lot of patients in the crosshairs.
Sources
- White House: Presidential Proclamation on pharmaceutical tariffs. Full text of executive order including rate structure, exemptions, MFN pricing framework, and January 2029 sunset. April 2, 2026.
- Advisory Board: Analysis of 100% tariff structure, Section 232 legal basis, company exemptions (Pfizer, Merck, BMS, AstraZeneca), 120/180-day implementation timeline, 53% overseas manufacturing statistic. April 6, 2026.
- Politico: Confidential deals with major drugmakers; MFN pricing agreements; EU/Japan/South Korea/Switzerland 15% rate; UK 10% rate; new commerce investigation. April 2, 2026.
- Yale Budget Lab: Effective tariff rate 11.8% (highest since 1940s); price impact $760–$940 per household; GDP persistently 0.1% smaller; manufacturing +1.1% but crowded out by construction -2.5%, mining -1.0%. April 8, 2026.
- Jones Day: Legal analysis of Section 232 authority for pharmaceuticals; rate reduction framework; orphan drug and specialty exemptions; Commerce Department investigation findings. April 8, 2026.
Related coverage